Effect of a GnRH antagonist on GnRH agonist-implanted anestrous bitches.
Various combinations of gonadotropin-releasing hormone (GnRH) antagonists and long-acting GnRH agonists have been assessed in several species to prevent the "flare-up" effect that agonists cause on the pituitary-gonadal axis. To determine the effect of a single administration of the GnRH antagonist acyline in anestrous GnRH agonist-implanted domestic bitches, 19 dogs (canis familiaris) were randomly assigned to receive either 10mg sc deslorelin acetate (DA; n=6) or DA combined with 330 microg/kg sc acyline within the first 48 h (DA & ACY; n=13). These bitches were examined daily for detection of posttreatment flare-up, manifested as an estrous response during the month after treatment. In the DA and DA&ACY groups, an estrous response was detected in 6 of 6 and 9 of 12 (P<0.5) of the bitches, starting 5.3+/-1.3 and 10.1+/-1.8 d (mean+/-SEM, P=0.5), respectively, after treatment. Based on serum progesterone concentrations, ovulation occurred in 6 of 6 and 5 of 9 of these bitches (P=0.1). None of the dogs had any local or systemic side effects related to the treatments. In five DA and six DA&ACY bitches that could be followed up after the trial, interestrus intervals were 385+/-22.5 and 330+/-69.1 d, respectively (P>0.1). It was concluded that the current antagonist protocol prevented initial ovarian stimulation in one quarter of the treated dogs, whereas the stimulation period was postponed and ovulation was inhibited in approximately half of the remainder.
Valiente
C
C
Laboratory of Mineral Nutrition and Reproductive Physiology, Faculty of Veterinary Medicine, National University of La Plata, CC 296, Argentina.
Diaz
J D
JD
Rosa
D E
DE
Mattioli
G
G
García Romero
G
G
Gobello
C
C
D000780:Anestrus / Q000502:physiology*; D000818:Animals; D004285:Dogs / Q000502:physiology*; D004343:Drug Implants; D004971:Estrus / Q000187:drug effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors*; D009842:Oligopeptides / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects*; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000031:analogs & derivatives*
D004343:Drug Implants; D009842:Oligopeptides; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C109238:acyline; C066438:deslorelin